Form 4: Quest Diagnostics Executive Exercises Options and Sells Shares

Catherine T. Doherty, an EVP at Quest Diagnostics, exercised stock options and sold shares on November 27, 2024, according to a recent SEC filing.

Summary

• Catherine T. Doherty, an Executive Vice President at Quest Diagnostics, exercised 33,103 stock options at a price of $103.57 per share on November 27, 2024.
• Following the exercise, Ms. Doherty sold 4,803 shares at a weighted average price of $162.1435 and 28,300 shares at a weighted average price of $163.1346.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan.
• After these transactions, Ms. Doherty directly owns 68,412 shares and indirectly owns 4,392 shares through a 401(k)/SDCP plan.
• She also holds 0 non-qualified stock options.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions by an executive, which is neither positive nor negative for the company's overall performance.

Industry Context

This is a routine filing related to executive stock transactions and is common for publicly traded companies. It does not indicate any specific trend in the diagnostics industry.

Comparison to Industry Standards

• Executive stock transactions are a common practice across publicly traded companies, including those in the diagnostics industry such as Labcorp (LH) and Bio-Rad Laboratories (BIO).
• The use of Rule 10b5-1 trading plans is a standard method for executives to manage their stock sales while avoiding accusations of insider trading.
• The reported prices are within the typical range for stock transactions of this nature.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-arranged trading plan and do not indicate a change in the company's fundamentals.

Key Dates

Keywords

stock options, insider trading, SEC Form 4, Quest Diagnostics, executive compensation, Rule 10b5-1, share sale